StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3067% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Xenetic Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Xenetic Biosciences's ebitda for the twelve months ending Dec 31, 2021 was -$5.75M. For fiscal 2022 it was -$6.72M. The highest annual figure on record is -$5.75M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$6.72M–
FY2021Dec 31, 2021-$5.75M–
FY2020Dec 31, 2020-$13.94M–
FY2015Dec 31, 2015-$9.77M–
FY2014Dec 31, 2014-$12.84M–
FY2013Dec 31, 2013-$8.56M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2021Dec 31, 2021-$1.87M–
Q3 FY2021Sep 30, 2021-$1.38M–
Q2 FY2021Jun 30, 2021-$1.13M–
Q4 FY2020Dec 31, 2020-$1.22M–
Q3 FY2020Sep 30, 2020-$10.50M–
Q2 FY2020Jun 30, 2020-$982.26K–
Q3 FY2016Sep 30, 2016-$2.24M–
Q2 FY2016Jun 30, 2016-$43.25M–

More Xenetic Biosciences figures

See a number that looks wrong?